SEL Type 2 Diabetes Update: Focus on GLP-1 Analogues

This webinar aims to inform clinicians of the updates to the SEL CESEL Type 2 diabetes guide and accompanying SEL GLP-1 guidance. Both guidelines have been updated to incorporate the NICE February 2026 recommendations which is moving away from a glucose/HbA1c focused treatment towards an earlier cardio-renal-metabolic risk reduction approach. This is a series of two webinars with the first focusing on the increased role of SGLT2 inhibitors and the second focusing on GLP-1 prescribing.

By the end of the session 1 you should be familiar with:

• The CESEL Type 2 diabetes (T2DM) guide which has been updated to incorporate NICE February 2026 recommendations

• Current achievement of 3 treatment targets and 8 care processes

• The role of SGLT-2 inhibitors and appropriate prescribing

• Where to access guidance and resources

By the end of the session 2 you should be familiar with:

• The role of GLP-1 receptor agonists

• Appropriate prescribing including initiation and titration

• Where to access guidance and resources